← Back to Search

Antibiotic Lock Therapy

Mino-Lok for Catheter-Associated Infections

Phase 3
Waitlist Available
Research Sponsored by Leonard-Meron Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights

Study Summary

This trial will compare the efficacy and safety of MLT to that of the control arm in the treatment of CRBSI/CLABSI.

Eligible Conditions
  • Catheter-Associated Infections

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to a catheter failure event.
Secondary outcome measures
All-cause mortality
Clinical Cure
Microbiological eradication
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Mino-Lok Therapy (MLT)Experimental Treatment1 Intervention
Standard of care plus MLT. MLT contains minocycline with EDTA and ethanol.
Group II: Standard of CareActive Control1 Intervention
Antibiotic lock + standard of care antibiotics. The standard of care antibiotic will be chosen by the investigator at the time of the infection.

Find a Location

Who is running the clinical trial?

Leonard-Meron Biosciences, Inc.Lead Sponsor
1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are being monitored as part of this research?

"That is correct, the clinical trial is still recruiting patients according to the information available on clinicaltrials.gov. The study was initially posted on February 13th, 2018, and was last updated on April 18th, 2022. A total of 144 participants are being sought at 17 different locations."

Answered by AI

What are the potential dangers associated with Mino-Lok?

"Mino-Lok is considered safe according to our team's 3-point scale. This is due to Phase 3 trial data, which provides strong evidence for both safety and efficacy."

Answered by AI

Are researchers actively looking for new participants for this experiment?

"The website clinicaltrials.gov has the latest information on this trial, which is still recruiting participants. The listing was first posted on February 13th, 2018 and updated as recently as April 18th, 2022."

Answered by AI

In how many different locations is this experiment being conducted today?

"Georgetown University Hospital in Washington, University of Florida Shands Hospital in Gainesville, and Indiana Blood and Marrow Institute in Indianapolis are 3 out of the 17 locations currently enrolling patients for this trial."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI
2018. "Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02901717.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top